Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120888454 | 12088845 | 4 | F | 20151030 | 20160720 | 20160218 | 20160801 | EXP | JP-ROCHE-1685126 | ROCHE | 14.88 | YR | M | Y | 0.00000 | 20160801 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120888454 | 12088845 | 1 | PS | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 375 MG/M2 TO 500 MG. | 103705 | 500 | MG | SOLUTION FOR INFUSION | /wk | ||||||
| 120888454 | 12088845 | 2 | SS | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 103705 | 3.7 | G | SOLUTION FOR INFUSION | QD | |||||||
| 120888454 | 12088845 | 3 | SS | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 103705 | 2 | G | SOLUTION FOR INFUSION | QD | |||||||
| 120888454 | 12088845 | 4 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 30-80 MG | 0 | ||||||||||
| 120888454 | 12088845 | 5 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 0 | 70 | MG | |||||||||
| 120888454 | 12088845 | 6 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 0 | 60 | MG | |||||||||
| 120888454 | 12088845 | 7 | C | TAVEGYL | CLEMASTINE FUMARATE | 1 | Oral | 0 | 300 | MG | |||||||||
| 120888454 | 12088845 | 8 | C | CALONAL | ACETAMINOPHEN | 1 | Oral | 0 | 1 | MG | |||||||||
| 120888454 | 12088845 | 9 | C | PERSANTIN | DIPYRIDAMOLE | 1 | Oral | 0 | 300 | MG | |||||||||
| 120888454 | 12088845 | 10 | C | AMLODIPINE BESILATE | AMLODIPINE BESYLATE | 1 | Oral | 0 | 5 | MG | |||||||||
| 120888454 | 12088845 | 11 | C | SULFAMETHOXAZOLE AND TRIMETHOPRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 0 | 2 | DF | TABLET | ||||||||
| 120888454 | 12088845 | 12 | C | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | 0 | 1500 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 120888454 | 12088845 | 1 | Nephrotic syndrome |
| 120888454 | 12088845 | 4 | Nephrotic syndrome |
| 120888454 | 12088845 | 9 | Nephrotic syndrome |
| 120888454 | 12088845 | 12 | Nephrotic syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 120888454 | 12088845 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 120888454 | 12088845 | Osteonecrosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 120888454 | 12088845 | 1 | 20150518 | 20150608 | 0 | |
| 120888454 | 12088845 | 2 | 20150525 | 0 | ||
| 120888454 | 12088845 | 3 | 20150601 | 0 | ||
| 120888454 | 12088845 | 4 | 201409 | 20150914 | 0 | |
| 120888454 | 12088845 | 5 | 20160527 | 0 | ||
| 120888454 | 12088845 | 6 | 20150603 | 201509 | 0 | |
| 120888454 | 12088845 | 7 | 20150518 | 20150608 | 0 | |
| 120888454 | 12088845 | 8 | 20150518 | 20150608 | 0 | |
| 120888454 | 12088845 | 9 | 20140916 | 0 | ||
| 120888454 | 12088845 | 10 | 20150501 | 0 | ||
| 120888454 | 12088845 | 11 | 20150518 | 0 | ||
| 120888454 | 12088845 | 12 | 20150430 | 0 |